Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02201277 · ClinicalTrials.gov registry record · NA

ODEN Trial: Option vs. Denali IVC Filters

A NA study, sponsored by University of California, San Francisco.

Terminated
Registry status
NA
Development phase
45
Enrollment target

NCT02201277: Clinical Trial NA study, sponsored by University of California, San Francisco.

NCT02201277 is a NA study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02201277, a NA study, was terminated before completion, sponsored by University of California, San Francisco.

TERMINATED
Registry status
NA
Development phase
45 participants
Enrollment target

Study Summary

This research study is a prospective randomized trial evaluating the relative safety of two inferior vena cava (IVC) filters used to prevent the migration of potentially dangerous deadly blood clots from the legs to the lung in patients who cannot take blood thinners. All eligible patients will have been ordered to have a IVC filter placed by their primary medical team and filters will be placed in these patients whether or not they wish to participate in this trial as part of standard of care. The investigators will follow up with patients 30 days after IVC filter placement and ask them to come back for filter removal if medically appropriate. If removal is not medically appropriate in 30 days, the investigators will attempt to schedule removal every 30 days after initial placement. Primary outcome measures will be IVC filter complications such as filter penetration through the IVC wall and into other organs, filter tilt, filter migration, filter fracture and clots formed within the filter. All of these are reported complications of all IVC filters. The research also aims to improve the standard of care for IVC filter patient follow up as the FDA and Society of Interventional Radiology recommend that IVC filters be removed as soon as it is safe to do so. Hypothesis: The investigators hypothesize that there is no significant difference in efficacy and complication rate between the Option and the Denali filter.

Primary Outcome

Using imaging analysis, patients will resume their standard care as normal but be encouraged to come back in 30 days for imaging followup and removal. other than that we will look at all available CT and xray imaging that clearly shows the filter and IVC vessel walls. We will count how many participants have penetration of the IVC greater than 3mm and the number of days since placement at imaging timepoints. The number of struts or hooks per filter with penetration will also be recorded.

Interventions

  • DEVICE Filter Placed

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2014-05-27
Est. Completion 2018-04-27
Phase NA

Why NCT02201277 stopped before completion

NCT02201277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Filter Placed is the first listed.

NCT02201277 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02201277 about?

NCT02201277 is a clinical study titled "ODEN Trial: Option vs. Denali IVC Filters". This research study is a prospective randomized trial evaluating the relative safety of two inferior vena cava (IVC) filters used to prevent the migration of potentially dangerous deadly blood clots from the legs to the lung in patients who cannot take blood thinners. All eligible patients will have...

What is the current status of trial NCT02201277?

This trial is currently terminated. It is a NA study. The enrollment target is 45 participants. The study started on 2014-05-27. Estimated completion is 2018-04-27.

What interventions are being tested in trial NCT02201277?

The interventions under investigation include: Filter Placed (DEVICE).

Who is sponsoring clinical trial NCT02201277?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02201277's enrollment target sits among peer trials

45 1411th of 2000 higher than 578 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02201277, the US trial registry maintained by the National Library of Medicine. NCT02201277 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.